Xiamen Amoytop Biotech Co.Ltd(688278)
Special instructions and independent opinions of independent directors on the company’s external guarantees in 2021, in accordance with the China Securities Regulatory Commission’s listed company governance standards and the guidelines for the supervision of listed companies No. 8 – regulatory requirements for capital transactions and external guarantees of listed companies, we, as independent directors of Xiamen Amoytop Biotech Co.Ltd(688278) (hereinafter referred to as the “company”), After careful verification of the company’s external guarantee in 2021, we hereby issue special instructions and independent opinions as follows:
1. Special description
During the reporting period, the company did not have any external guarantee in any form, and there was no external guarantee in previous years that lasted until the reporting period.
2. Independent opinion
During the reporting period, the company strictly abided by the relevant provisions of relevant laws and regulations on guarantee matters, defined the object, scope and approval authority of external guarantee in the articles of association and external guarantee management system, strictly standardized the company’s external guarantee behavior, controlled the external guarantee risk, and did not damage the interests of the company and shareholders.
(there is no text on this page, which is the signature page of Xiamen Amoytop Biotech Co.Ltd(688278) independent directors’ special instructions and independent opinions on the company’s external guarantee in 2021) independent directors:
Jiang Xiaohui, Zhou Kefu, Liu Qi
March 30, 2022
